Dr. Mohamed Ali El-Shahawy, MD

Dr. El-Shahawy practices at Fresenius Kidney Care Paramount in Los Angeles, California.

Dr. El-Shahawy's NPI, 1760411151, was assigned on June 30, 2006. Dr. El-Shahawy graduated from Cairo University School of Medicine in 1979. Dr. El-Shahawy holds California license A42315.

Dr. El-Shahawy's primary practice is Fresenius Kidney Care Paramount, at 5830 Whittier Blvd, Los Angeles, CA 90022 in Los Angeles County. The practice phone is (323) 842-5772.

Dr. El-Shahawy's primary practice is Fresenius Kidney Care Paramount in Los Angeles, California. Dr. El-Shahawy is also affiliated with Keck Hospital of USC. The medical group on file is City of Hope. Dmand AI also links Dr. El-Shahawy to 4 more hospitals, 2 dialysis centers and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. El-Shahawy practices, 7 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. El-Shahawy's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. El-Shahawy is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. El-Shahawy's licenses on file in 5 states: California, West Virginia, Massachusetts, Pennsylvania and Connecticut.

Dmand AI lists electrolyte disorders, fluid and electrolyte imbalances, kidney failure and kidney stones among the conditions Dr. El-Shahawy treats.

CMS data shows 1,068 Medicare services from Dr. El-Shahawy across 7 procedure codes in 2024, for 175 Medicare patients. Medicare paid $130,373 for them.

CMS counts 175 Medicare patients who saw Dr. El-Shahawy in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 88% are also on Medicaid. Their average risk score is 6.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. El-Shahawy's median patient age at 65, with 52% women.

In 2024, Dr. El-Shahawy wrote 1,345 Medicare Part D claims for 118 patients. 76% of them were for generic drugs. CMS names the drug for 955 of them, across 37 drugs with 11 or more claims each, at $206,263 in total drug cost. In 2023, CMS named 1,112 claims across 40 drugs.

Dr. El-Shahawy accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. El-Shahawy.

Dmand AI links Dr. El-Shahawy to 13 clinical trials, 7 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Nephritis, Hereditary, Polycystic Kidney, Autosomal Dominant and Renal Insufficiency, Chronic. Biogen sponsors the most, 2. Open Payments lists research payments to Dr. El-Shahawy that name 1 trial.

CMS Open Payments shows 174 general payments to Dr. El-Shahawy from 27 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 43% of the total. AstraZeneca Pharmaceuticals LP paid the most, $10,481. It also lists 21 research payments totaling $7,033 from 2016 to 2025, naming 1 clinical trial.

Dr. El-Shahawy graduated from Cairo University School of Medicine in 1979. Dr. El-Shahawy is a member of ASN.

Dr. El-Shahawy is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.